Highlights and Quick Summary
- EBIT for the quarter ending September 30, 2022 was $-17.4 Million (a -49.76% decrease compared to previous quarter)
- Year-over-year quarterly EBIT decreased by -66.57%
- Annual EBIT for 2021 was $-178 Million (a 1.7% increase from previous year)
- Annual EBIT for 2020 was $-175 Million (a 75.71% increase from previous year)
- Annual EBIT for 2019 was $-99.5 Million (a 5.56% increase from previous year)
- Twelve month EBIT ending September 30, 2022 was $-154 Million (a -14.96% decrease compared to previous quarter)
- Twelve month trailing EBIT decreased by -13.18% year-over-year
Trailing EBIT for the last four month:
30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
---|---|---|---|
$-154 Million | $-181 Million | $-176 Million | $-178 Million |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT of BioCryst Pharmaceuticals, Inc.
Most recent EBITof BCRX including historical data for past 10 years.Interactive Chart of EBIT of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. EBIT for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | – | $-17.45 | $-34.72 | $-49.96 | – |
2021 | $-52.18 | $-44.58 | $-29.58 | $-51.38 | $-177.72 |
2020 | $-52.41 | $-42.86 | $-38.51 | $-40.98 | $-174.76 |
2019 | $-0.11 | $-35.1 | $-34.92 | $-29.33 | $-99.46 |
2018 | $-25.26 | $-28.49 | $-18.25 | $-22.21 | $-94.22 |
2017 | $-17.86 | $-13.35 | $-15.52 | $-10.69 | $-57.41 |
2016 | $-8.19 | $-9.24 | $-12.13 | $-19.05 | $-48.61 |
2015 | $-17.19 | $-13.16 | $5.34 | $-14.43 | $-39.44 |
2014 | $-15.16 | $-11.61 | $-11.62 | $-7.39 | $-45.77 |
2013 | $-6.33 | $-6.93 | $-12.14 | $-5.32 | $-30.72 |
2012 | $-10.7 | $-8.02 | $-10.18 | $-5.0 | $-33.89 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology